Merck & Co (NYSE: MRK) has racked up another European approval for its anti-PD-1 workhorse Keytruda (pembrolizumab), as a first-line treatment for certain people with head and neck cancer.
The approval covers Keytruda as monotherapy or in combination with chemo, to treat people with cancer expressing PD-L1.
The decision was based on findings from the Phase III KEYNOTE-048 trial, which showed a significant improvement in overall survival (OS) for this patient population.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze